Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.42 |
| ▸ | HRH1 | P35367 | 2/20 | 0.41 |
| ▸ | EBP | Q15125 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 2/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1588123 | 0.98 | HTR2A (0.46) | HTR2ASIGMAR1HRH1EBPHTR2C | |
| SCHEMBL31283252 | 0.85 | OPRM1 (0.42) | HTR2ASIGMAR1HTR2CDRD2SLC6A2 | |
| SCHEMBL4359521 | 0.85 | OPRM1 (0.42) | HTR2ASIGMAR1HTR2CDRD2SLC6A2 | |
| SCHEMBL12021583 | 0.84 | MAOA (0.47) | HTR2ASIGMAR1EBPHTR2CDRD2 | |
| SCHEMBL17768526 | 0.82 | HTR2A (0.41) | HTR2ASIGMAR1HRH1EBPHTR2C | |
| SCHEMBL17768500 | 0.82 | MEN1 (0.41) | HTR2ASIGMAR1HRH1EBP | |
| SCHEMBL17768463 | 0.78 | HTR2A (0.40) | HTR2ASIGMAR1HRH1HTR2CDRD2 | |
| SCHEMBL21130578 | 0.78 | SIGMAR1 (0.57) | SIGMAR1EBP | |
| SCHEMBL17779090 | 0.76 | CHRM2 (0.52) | SIGMAR1EBP | |
| SCHEMBL17014512 | 0.76 | SIGMAR1 (0.44) | SIGMAR1EBPMAPK1SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230104936-A1 | TRPML MODULATORS | CASMA THERAPEUTICS, INC. | 2023-04-06 | — | — | US | disclosed |
| EP-4076423-A1 | TRPML MODULATORS | Casma Therapeutics, Inc. (US) | 2022-10-26 | — | — | EP | disclosed |
| CN-115087440-A | TRPML modulators | 卡斯玛治疗公司 | 2022-09-20 | — | — | CN | disclosed |
| WO-2021127337-A1 | TRPML MODULATORS | CASMA THERAPEUTICS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021127337-A1 | TRPML MODULATORS | CASMA THERAPEUTICS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| US-10407428-B2 | Spiro-isoquinoline-1,4′-piperidine compounds having multimodal activity against pain | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2019-09-10 | — | — | US | disclosed |
| EP-3221314-B1 | SPIRO-ISOQUINOLINE-1,4'-PIPERIDINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS SA (ES) | 2019-07-03 | — | — | EP | disclosed |
| US-20180111935-A1 | SPIRO-ISOQUINOLINE-1,4'-PIPERIDINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2018-04-26 | — | — | US | disclosed |
| EP-3221314-A1 | SPIRO-ISOQUINOLINE-1,4'-PIPERIDINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2017-09-27 | — | — | EP | disclosed |
| WO-2016078770-A1 | SPIRO-ISOQUINOLINE-1,4'-PIPERIDINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2016-05-26 | — | — | WO | disclosed |
| US-20110092529-A1 | 1,2,4-Triazole Derivatives and Their Use as Oxytocin Antagonists | PFIZER INC. | 2011-04-21 | — | — | US | disclosed |
| US-20110092529-A1 | 1,2,4-Triazole Derivatives and Their Use as Oxytocin Antagonists | PFIZER INC. | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10407428-B2 | Spiro-isoquinoline-1,4′-piperidine compounds having multimodal activity against pain | OPRD1, OPRK1, OPRL1 | HTR2A 93/4885SIGMAR1 5/4885HRH1 1105/4885 |
| US-20230104936-A1 | TRPML MODULATORS | TRPM2, TRPM4, TRPM5 | HTR2A 376/4885SIGMAR1 683/4885HRH1 1035/4885 |
| US-20180111935-A1 | SPIRO-ISOQUINOLINE-1,4'-PIPERIDINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | OPRD1, OPRK1, OPRL1 | HTR2A 93/4885SIGMAR1 5/4885HRH1 1108/4885 |
| US-20110092529-A1 | 1,2,4-Triazole Derivatives and Their Use as Oxytocin Antagonists | OXTR, PRLHR, KISS1R | HTR2A 889/4885SIGMAR1 748/4885HRH1 3330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.